TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06068660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Goal-Oriented Care program
Description: The Goal-Oriented Care Interventions The GOC intervention included the following steps: respecting the participant's values in setting goals, considering direct and indirect factors influencing the goals, communicating and setting goals, implementing goal-oriented strategies, and evaluating goals while adjusting the content of the strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The routine health education
Description: The control group received routine education, which consisted of oral education and provision of educational pamphlets by nurses during hospitalization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The routine health education
Description: The control group received routine education, which consisted of oral education and provision of educational pamphlets by nurses during hospitalization.
Study: NCT06057545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envarsus®
Description: Treatment sequence: 4 weeks prolonged-release tacrolimus (Envarsus®) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envarsus®
Description: Treatment sequence: 4 weeks prolonged-release tacrolimus (Envarsus®) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf
Description: Treatment sequence: 4 weeks intermediate-release tacrolimus (Prograf®) twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf
Description: Treatment sequence: 4 weeks intermediate-release tacrolimus (Prograf®) twice daily
Study: NCT05989607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower sugar flavored water
Description: A commercially available low sugar flavored water (2.88kcal/100ml; 0.57(sugar) +0.03 (stevia)=0.60g/100ml; sodium 7.9mg/100ml).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain Water
Description: Commercially available bottled, spring water.
Study: NCT04226807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Postpartum Phone Call
Description: Participants receive a phone call 2-3 weeks after birth asking about overall wellbeing, screening for complications and postpartum depression and referring to lactation or WIC as needed.
Study: NCT05937633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transformational Education Programme
Description: An evidence based targeted transformational leadership programme is designed to provide charge nurses an opportunity to develop transformational leadership knowledge and skill.~The programme includes a 2-day activity based educational training. A prereading booklet will be given prior to the educational activity aimed at enhancing the engagement of the participants. The educational programme comprises of the following contents: Concept of leadership and work engagement, transactional and transformational leadership styles, advantages, and disadvantages of transformational leaders. qualities of transformational leaders, 5- Practices of exemplary leadership practice, the 10 commitments of transformational leadership and developing transformational leadership skills.
Study: NCT04987892

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UroLift System
Description: Prostatic lift

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin Hydrochloride
Description: Tamsulosin HCl 0.4mg
Study: NCT01019291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formaldehyde and NO2 (Exposure to indoor pollutants)
Description: Exposure to indoor pollutants (Formaldehyde and NO2) in a randomized way, followed by bronchial challenge test with house dust mite extract.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formaldehyde and NO2 (Exposure to indoor pollutants)
Description: Exposure to indoor pollutants (Formaldehyde and NO2) in a randomized way, followed by bronchial challenge test with house dust mite extract.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formaldehyde and NO2 (Exposure to indoor pollutants)
Description: Exposure to indoor pollutants (Formaldehyde and NO2) in a randomized way, followed by bronchial challenge test with house dust mite extract.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Exposure to indoor pollutants)
Description: Exposure to indoor pollutants (placebo) in a randomized way, followed by bronchial challenge test with house dust mite extract.
Study: NCT05134090

Intervention type: DEVICE
Intervention: Ovaian tissue explant
Description: Ovarian tissue explant for cryopreservation of ovarian tissue

Intervention type: DEVICE
Intervention: Ovaian tissue explant
Description: Ovarian tissue explant for cryopreservation of ovarian tissue
Study: NCT06290063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fsCBD Cannabidiol
Description: Full Spectrum hemp-derived CBD (fsCBD; 200mg CBD/4mg THC) capsules produced by Ecofibre/Ananda Hemp will be used

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bsCBD Cannabidiol
Description: Broad spectrum hemp-derived CBD (bsCBD; 200mg CBD) capsules produced by Ecofibre/Ananda Hemp will be used

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm; capsules produced by Ecofibre/Ananda Hemp will be used
Study: NCT06396793

Intervention type: OTHER
Intervention: no intervention because it is an observational study
Description: it is an observational study thus there is no intervention
Study: NCT05387226

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Virus Injection(RT-01)
Description: RT-01 will be administered intravenously on day 1 and 6, and every 8 weeks thereafter (up to 6 times)
Study: NCT05413174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnoanalgésia
Description: Use of Ericksonienne hypnosis in the medical field, aiming to dissociate the patient from the intervention in order to modify his or her perception of pain and limit anxiety.~Ericksonienne hypnosis will use during ultrasound-guided biopsy in radiology ward.
Study: NCT05000892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab , Carboplatin, Nab-paclitaxel
Description: Patients receive Sintilimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
Study: NCT05062083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-MC1
Description: Up to 20 mCi injected IV followed by PET scanning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-PS13
Description: Up to 20 mCi injected IV followed by PET Scanning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: Ketoprofen 75 mg orally once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: celecoxib 600 mg orally once
Study: NCT04997928

Intervention type: OTHER
Intervention: Serum PAI-1 alpha analysis.
Description: After all four groups of patients have given their consent for the study, a sample of 5cc blood will be obtained once for the PAI-1 analysis.

Intervention type: OTHER
Intervention: Serum PAI-1 alpha analysis.
Description: After all four groups of patients have given their consent for the study, a sample of 5cc blood will be obtained once for the PAI-1 analysis.

Intervention type: OTHER
Intervention: Serum PAI-1 alpha analysis.
Description: After all four groups of patients have given their consent for the study, a sample of 5cc blood will be obtained once for the PAI-1 analysis.

Intervention type: OTHER
Intervention: Serum PAI-1 alpha analysis.
Description: After all four groups of patients have given their consent for the study, a sample of 5cc blood will be obtained once for the PAI-1 analysis.
Study: NCT05914246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIOLA proximal seal
Description: VIOLA proximal seal system for maintenance of hemostasis when suturing the aortic anastomoses
Study: NCT04201821

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fecal microbial transplantation (FMT)
Description: Fecal microbial transplantation (FMT) is the infusion of intestinal microbiota from healthy donors.
Study: NCT06099210

Intervention type: DIAGNOSTIC_TEST
Intervention: Glasgow coma scale
Description: Closed tach brain injury due to external force was included according to the GCS score
Study: NCT05121363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2858 injection
Description: TQB2858 is an anti-programmed death receptor 1(anti-PD-1) /Transforming growth factor-β(TGF-β )bi-functional fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride capsules
Description: Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.
Study: NCT05559021

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Therapy Treatments
Description: • Myofascial approach: After the bibliographic review of myofascial therapy treatments in fibromyalgia patients based on the articles by CastroSánchez AM et al., and an expert consensus, the following approach was decided: patients would have 4 sessions in total with 1 session per week of 30 minutes each.~* Transverse planes in the thoracolumbar fascia (TCL) and abdomen: Performing a myofascial induction as described by Pilat.~* Transverse planes at C7-D3 and sternum: Performing a myofascial induction as described by Pilat.~* Suboccipital inhibition: Performing a myofascial induction as described by Pilat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Mobilizations Approach
Description: • Approach with passive mobilizations: After the literature review of manual therapy treatments in fibromyalgia patients and a consensus of experts in Manual Therapy with more than 15 years of experience, the following approach was agreed upon by the expert: patients would have 4 sessions in total with 1 session per week of 30 minutes each.~* Postero-anterior cervical sliding~* Postero-anterior lumbar slippage~* Postero anterior dorsal slippage
Study: NCT06371287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treinamento Auditivo Musical
Description: Auditory training with a focus on musicality. The skills trained will be: figure-ground for instrumental sounds, sequential figure-ground, directed listening, duration of sounds, frequency of sounds, rhythm (temporal structuring), auditory closure and audiovisual memory, with a focus on temporal processing, working memory and attention selective on an increasing scale of difficulty. The frequency ranges of instrumental sounds are from 200 to 4000 Hz, composed of the following instruments: guitar, vibraphone, piano, flute and drum.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This placebo approach will be to demonstrate the influence of musical exposure without exercises with structuring auditory skills and compare with the TAM group.~The song Sonata for two pianos in D major, K448, by Mozart, will be used. The films selected were: Cirque Du Soleil, entitled The Journey of Man; Chaplin collection with the following films: Modern Times, The Great Dictator, In Search of Gold and Footlights. The choice of the order of the films will be random, as proposed by Freire (2009).
Study: NCT05053802

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Microwave ablation plus Camrelizumab
Description: Tumor received treatment of microwave ablation and received no more than 16 cycles of Camrelizumab

Intervention type: DEVICE
Group type: OTHER
Intervention: Microwave ablation
Description: Tumor received treatment of microwave ablation
Study: NCT05627206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Management + For Moms
Description: Psychosocial intervention conducted by a trained Wellbeing-Community health worker. Adapted from Problem Management +, thinking healthy and Strong Minds-Strong Communities intervention to target women with small children and mental health symptoms living in low-resourced settings. Combines several evidence-based strategies such us psychoeducational, motivational interviewing, cognitive restructuring and relaxation exercises. Organized in 10 weekly sessions (8 individual 2 in group) provided in-person, by phone or virtually.
Study: NCT04793620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TQL1055
Description: Semisynthetic saponin adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Acellular pertussis vaccine
Description: Acellular pertussis vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine
Description: Acellular pertussis vaccine
Study: NCT05328583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS5685；Placebo
Description: Drug1: HRS5685 Single dose in group A-F and multiple doses in group G-H~Drug2: Placebo Single dose in group A-F and multiple doses in group G-H

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS5685；Placebo
Description: Drug1: HRS5685 Single dose in group A-F and multiple doses in group G-H~Drug2: Placebo Single dose in group A-F and multiple doses in group G-H

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS5685；Placebo
Description: Drug1: HRS5685 Single dose in group A-F and multiple doses in group G-H~Drug2: Placebo Single dose in group A-F and multiple doses in group G-H

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS5685；Placebo
Description: Drug1: HRS5685 Single dose in group A-F and multiple doses in group G-H~Drug2: Placebo Single dose in group A-F and multiple doses in group G-H

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS5685；Placebo
Description: Drug1: HRS5685 Single dose in group A-F and multiple doses in group G-H~Drug2: Placebo Single dose in group A-F and multiple doses in group G-H

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS5685；Placebo
Description: Drug1: HRS5685 Single dose in group A-F and multiple doses in group G-H~Drug2: Placebo Single dose in group A-F and multiple doses in group G-H

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS5685；Placebo
Description: Drug1: HRS5685 Single dose in group A-F and multiple doses in group G-H~Drug2: Placebo Single dose in group A-F and multiple doses in group G-H

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS5685；Placebo
Description: Drug1: HRS5685 Single dose in group A-F and multiple doses in group G-H~Drug2: Placebo Single dose in group A-F and multiple doses in group G-H
Study: NCT05207670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (Cohorts A-C)
Description: Participants will receive SC mosunetuzumab for up to 17 cycles and for optional maintenance (Cohort A only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (Cohorts A-C)
Description: Participants will receive SC mosunetuzumab for up to 17 cycles and for optional maintenance (Cohort A only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (Cohorts A-C)
Description: Participants will receive SC mosunetuzumab for up to 17 cycles and for optional maintenance (Cohort A only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (Cohorts D-E)
Description: Participants will receive SC mosunetuzumab for up to 34 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (Cohorts D-E)
Description: Participants will receive SC mosunetuzumab for up to 34 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants can be treated with tocilizumab if they present with CRS after receiving mosunetuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants can be treated with tocilizumab if they present with CRS after receiving mosunetuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants can be treated with tocilizumab if they present with CRS after receiving mosunetuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants can be treated with tocilizumab if they present with CRS after receiving mosunetuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants can be treated with tocilizumab if they present with CRS after receiving mosunetuzumab
Study: NCT06506461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given Subcutaneous (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gene-modified CD34+ cells
Description: Given Intravenous (IV)
Study: NCT04838769

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: REZŪM
Description: Subjects randomized to receive the REZŪM treatment will receive standardized treatment, following the Instruction for Use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alpha blocker and 5-alpha reductase inhibitor
Description: Subjects assigned to dual drug therapy will be treated with the local formulary preferred choice of commercially available urinary selective alpha blocker and 5-alpha reductase inhibitor. This arm will therefore represent local standard of care.
Study: NCT05590689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliolan
Description: A repetitive dose of Gliolan will be administrated in combination with radiotherapy (radiodynamic therapy)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiodynamic therapy
Description: Radiotherapy will be performed in combination with Gliolan administration
Study: NCT04886154

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY-2Gen low dose vaccine
Description: MenABCWY-2Gen low dose vaccine is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the ABCWY low dose Group in study Phase I, ABCWY low dose_06 Group and ABCWY low dose_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY low dose_01 Group, ABCWY low doseS_02 Group and ABCWY low doseS_06 Group in study Phase II (Sourcing).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY-2Gen low dose vaccine
Description: MenABCWY-2Gen low dose vaccine is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the ABCWY low dose Group in study Phase I, ABCWY low dose_06 Group and ABCWY low dose_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY low dose_01 Group, ABCWY low doseS_02 Group and ABCWY low doseS_06 Group in study Phase II (Sourcing).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY-2Gen low dose vaccine
Description: MenABCWY-2Gen low dose vaccine is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the ABCWY low dose Group in study Phase I, ABCWY low dose_06 Group and ABCWY low dose_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY low dose_01 Group, ABCWY low doseS_02 Group and ABCWY low doseS_06 Group in study Phase II (Sourcing).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY-2Gen low dose vaccine
Description: MenABCWY-2Gen low dose vaccine is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the ABCWY low dose Group in study Phase I, ABCWY low dose_06 Group and ABCWY low dose_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY low dose_01 Group, ABCWY low doseS_02 Group and ABCWY low doseS_06 Group in study Phase II (Sourcing).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY-2Gen low dose vaccine
Description: MenABCWY-2Gen low dose vaccine is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the ABCWY low dose Group in study Phase I, ABCWY low dose_06 Group and ABCWY low dose_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY low dose_01 Group, ABCWY low doseS_02 Group and ABCWY low doseS_06 Group in study Phase II (Sourcing).
Study: NCT05614596

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CT guided and Flouroscopic guided injection of corticosteroid and local anathesia
Description: Patients will be grouped into two groups, the first group (Group A) included patients who were subjected to fluoroscopic guided injection, and the second group (Group B) will include patients who were subjected to CT guided injections.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CT guided and Flouroscopic guided injection of corticosteroid and local anathesia
Description: Patients will be grouped into two groups, the first group (Group A) included patients who were subjected to fluoroscopic guided injection, and the second group (Group B) will include patients who were subjected to CT guided injections.
Study: NCT06425900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Winlevi (Clascoterone) cream 1%
Description: Dosed twice daily (BID)
Study: NCT05164991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visuo-tactile stimulations of the right hand
Description: Participants lay down in the magnetic resonance (MR) scanner are presented with visual stimuli (videos of the virtual rubber hand - visual stroking) simultaneously in real time with tactile stimuli (robotic stroking of the participant's hand - tactile stroking). An MR-compatible robot systematically provides the tactile stroking on the participant's hand. MR-compatible goggles show the visual stroking. Patterns of long and short robotic movements will be provided.
Study: NCT06078501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 400mcg buccal
Description: Misoprostol 400mcg buccal administration 2-3 hours prior to procedure